ITOC, or iTonic Holdings Ltd., is a small Beijing-based healthcare technology company that develops and commercializes treatment planning software and related devices used in brachytherapy — a form of radiation therapy in which radioactive sources are implanted inside a patient to shrink tumors. Its core product is the FTTPS planning platform, supplemented by medical auxiliary supplies. The company, formerly known as Pheton Holdings, trades on the Nasdaq Capital Market with a market value of roughly $12 million.
In the current session the stock is trading at $1.60, down 13.51% from the previous completed session's close of $1.85, a decline of $0.25. The direction is unambiguously negative, and the print represents a fresh 52-week low. No verified company-specific catalyst explains the move; the selling is consistent with the absence of buyers in an extremely thin order book during a prolonged downtrend.
No verified news or fundamental catalyst found for today's decline. There is no press release, securities filing, analyst action, or corporate announcement in the public record preceding the session that would materially alter the investment case for a company of this size. What the trading record does support is a technical explanation: the stock is exceptionally thin — prints in individual minutes have totaled only a few hundred shares — so modest sell orders can move the quote several percentage points. That is consistent with a day's range that has already spanned from the low $1.70s down to $1.60 on very limited turnover.
The move also fits a well-established pattern of profit-taking and capital flight after a failed rebound attempt. The shares had rallied from about $1.63 in early November to an intraday high above $2.30 on November 11, then stalled and rolled over. Combined with a slide from roughly $5.19 in late August, today's weakness looks like continuation of a persistent structural downtrend in a speculative micro-cap rather than a reaction to information. There are legitimate standing overhangs — a securities class action filed against the company and its former identity, and a return to Nasdaq minimum-bid compliance in October achieved through a 16-for-1 share consolidation — but none of these is new today, and none can be linked to this specific session's timing.
Volume has not been meaningfully elevated relative to the trailing 30-day average of roughly 31,000 shares, which weakens any interpretation of today's move as an information-driven repricing and supports the thin-liquidity read. The decline does not appear to be a sector event: no broad medical-device or healthcare-technology catalyst is evident, and the move diverges sharply from the direction of large-cap benchmarks. The stock is trading well below any plausible moving-average support, having broken through the November lows, and the $1.60 area is now the reference level for a possible stabilization attempt. Beta in excess of 3.0 underscores how aggressively this name amplifies even small shifts in sentiment.
A score of 0 describes no meaningful news paired with a move that is routine for the stock; 100 describes transformative news paired with an extreme, rare price move. This event lands at 12 out of 100.
The news component is close to the floor: no verified catalyst exists, so fundamental materiality is essentially absent. The price component is modest as well. Today's 13.51% decline is roughly 2.4 times the stock's typical absolute daily move of about 5.6% over the past 60 sessions, and a move of that size or larger has occurred only three times in those 60 sessions. An unusual but not extreme move, with no verified news, produces a low combined score.
Attention now turns to the company's next interim financial disclosure, which will be the first real test of whether the recently reported revenue base and cash position can support operations. Cash of roughly $2.2 million against a trailing annual loss in the high single-digit millions leaves the balance sheet as the central variable, and any financing activity would be highly dilutive at current valuations. Investors will also watch for further developments in the pending securities litigation and for any additional Nasdaq notifications, since the listing has a history of bid-price deficiency. Analyst coverage is effectively absent, so price discovery will depend on company disclosure and order flow rather than published estimates. Key risks include continued illiquidity, widening losses, and the possibility that volatility of this magnitude persists without a fundamental trigger.
Tickeron's Trending AI Robots page is a curated window into the platform's automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup changes as conditions evolve. Visitors can compare approaches and identify strategies suited to their own objectives before deploying capital.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for ITOC moved into overbought territory on November 19, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ITOC just turned positive on November 12, 2026. Looking at past instances where ITOC's MACD turned positive, the stock continued to rise in 15 of 16 cases over the following month. The odds of a continued upward trend are 90%.
Following a +19.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where ITOC advanced for three days, in 87 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ITOC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ITOC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ITOC entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.792) is normal, around the industry mean (4.142). P/E Ratio (0.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.074) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ITOC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ITOC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices